8-K: Alpha Cognition Reports Strong ZUNVEYL Growth, $10.2M Revenue

Alpha Cognition Inc. announced its fiscal year 2025 financial and operational results, highlighting significant commercial momentum for its Alzheimer's treatment, ZUNVEYL, and a strong cash position.

Summary

• Alpha Cognition reported total revenues of $10.2 million for the full year ended December 31, 2025, including $6.8 million in ZUNVEYL net product revenue and $3.4 million in licensing revenue.
• Fourth quarter 2025 ZUNVEYL net product revenue was $2.5 million, with bottles dispensed increasing 62% quarter-over-quarter to 4,941.
• December 2025 marked the strongest sales month since ZUNVEYL's launch, with 1,859 bottles sold.
• The company executed a second national PBM contract, now having agreements with two of the four major PBMs relevant to long-term care.
• Prescribers increased 50% and cumulative homes with prescriptions grew 26% in Q4 2025.
• Selling, General & Administrative expenses significantly increased to $29.1 million in 2025 from $8.0 million in 2024, reflecting commercial investment.
• The operating loss for 2025 was $22.7 million, compared to $12.0 million in 2024.
• Net loss for 2025 was $20.7 million, compared to $14.8 million in 2024.
• Cash and cash equivalents totaled $66.0 million at year-end 2025, up from $48.5 million in 2024, supported by $40 million in net proceeds from an October 2025 capital raise.
• The company targets operational profitability in 2027 and expects a cash runway of approximately two years.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update. While losses increased, this is largely due to expected commercialization investments for ZUNVEYL, which is showing strong initial market traction and strategic payer access gains, supported by a solid cash position.

Positives

• ZUNVEYL generated $2.5 million in net product revenue in Q4 2025, contributing to $6.8 million for the full year, demonstrating strong commercial execution in its launch year.
• Bottles dispensed for ZUNVEYL increased by 62% quarter-over-quarter in Q4 2025, reaching 4,941, with December being the strongest month since launch.
• The company secured a second national PBM contract, expanding payer access for ZUNVEYL in the long-term care market.
• The prescriber base for ZUNVEYL grew by 50% and cumulative homes with prescriptions increased by 26% in Q4 2025, indicating broadening adoption.
• Cash and cash equivalents increased to $66.0 million by year-end 2025, providing an estimated two-year cash runway, bolstered by a $40 million capital raise.
• Research & Development expenses decreased to $1.9 million in 2025 from $3.9 million in 2024, reflecting the transition to a commercial stage company.
• Net loss per share improved to $(1.17) in 2025 from $(2.04) in 2024, despite a higher net loss, due to an increased number of shares outstanding.

Negatives

• The company reported an increased operating loss of $22.7 million in 2025, up from $12.0 million in 2024.
• Net loss widened to $20.7 million in 2025, compared to $14.8 million in 2024.
• Selling, General & Administrative expenses significantly increased to $29.1 million in 2025 from $8.0 million in 2024, reflecting substantial commercial investment that contributed to the increased losses.

Risks

• Ability to raise sufficient capital to implement plans for continued commercialization of ZUNVEYL.
• Efficacy and tolerability of ZUNVEYL.
• Ongoing regulatory oversight on the safety of ZUNVEYL.
• Market adoption of ZUNVEYL.
• Risks related to the company's intellectual property in relation to ZUNVEYL.
• Risks related to the commercial manufacturing, distribution, marketing, and sale of ZUNVEYL.
• Product liability risks.
• Risks related to ongoing clinical trials.
• Other risks as described in the company's most recent Annual Report on Form 10-K filed with the SEC on March 31, 2025.

Future Outlook

Alpha Cognition is focused on expanding its commercial footprint for ZUNVEYL, deepening prescriber engagement, and advancing towards operational profitability in 2027. The company expects two product approvals ex-US via its partner CMS in Asia and plans to initiate two new studies (CONVERGE and RESOLVE) to further support ZUNVEYL's positioning and assess its effects. Additionally, preclinical work for a sublingual ZUNVEYL formulation is expected to be completed, with advancement to the clinic in 2026 for mild-to-moderate AD.

Management Comments

• "2025 was a year of strong commercial execution for Alpha Cognition as we continued to build momentum for ZUNVEYL – the first new oral Alzheimers treatment approved in more than 15 years."
• "Were encouraged by the increasing rates of repeat ordering, indicating ZUNVEYL is moving beyond initial trial and becoming increasingly integrated into routine management in long-term care."
• "Importantly, we also executed a second national PBM contract, bringing us to two of the four major PBMs relevant to long-term care."
• "We enter the year well-capitalized and focused on expanding our commercial footprint, deepening prescriber engagement, and advancing toward operational profitability in 2027."

Industry Context

StockSavvy.ai notes that Alpha Cognition's focus on ZUNVEYL, a new oral Alzheimer's treatment, positions it in a high-need market with significant unmet medical needs. The emphasis on long-term care and securing PBM contracts is crucial for market penetration in the competitive neurodegenerative space. The development of a sublingual formulation could be a significant differentiator, addressing a key challenge for patients with dysphagia, potentially disrupting existing treatment paradigms dominated by older generation acetylcholinesterase inhibitors like donepezil and rivastigmine.

Comparison to Industry Standards

• The 62% quarter-over-quarter growth in ZUNVEYL bottles dispensed in Q4 2025 indicates strong initial market uptake, which is generally positive for a new drug launch in the biopharmaceutical sector, especially for a chronic condition like Alzheimer's.
• Securing two national PBM contracts is a critical step for market access, comparable to the early commercialization efforts seen with other novel Alzheimer's treatments, such as Biogen's Aduhelm or Eisai's Leqembi, where payer coverage significantly impacts adoption rates.
• The increase in SG&A expenses to $29.1 million in 2025, reflecting commercial investment, is typical for a company transitioning from R&D to commercial stage, similar to the ramp-up costs observed in other biopharma launches, though the magnitude of the operating loss ($22.7 million) highlights the significant investment required for market entry.
• The planned initiation of real-world effectiveness (BEACON) and Phase 4 (RESOLVE) studies aligns with industry best practices for post-market surveillance and further evidence generation, crucial for driving broader physician and payer acceptance, akin to strategies employed by major pharmaceutical companies for their flagship products.

Related Party Transactions

• The consolidated balance sheet shows a 'Current portion of promissory note related party' of $911,463 as of December 31, 2024, which was reduced to $0 by December 31, 2025, indicating a repayment or settlement of this related party debt.

Stakeholder Impact

• **Shareholders:** The strong commercial growth of ZUNVEYL and a healthy cash position provide positive indicators for future revenue generation and stability, though increased losses due to commercial investment may temper immediate profitability expectations. The capital raise in October 2025 likely diluted existing shareholders.
• **Patients (Alzheimer's):** ZUNVEYL offers a new oral treatment option, and the development of a sublingual formulation could significantly benefit patients with dysphagia, expanding access to medication.
• **Healthcare Providers:** Increased prescriber base and ongoing studies (BEACON, CONVERGE, RESOLVE) aim to provide more data on ZUNVEYL's effectiveness and tolerability, which could support broader adoption and integration into routine management.
• **Payers (PBMs):** The execution of a second national PBM contract improves market access and reimbursement for ZUNVEYL, which is beneficial for both the company and patients seeking coverage.

Next Steps

• Host a conference call and webcast on March 26, 2026, at 4:30 p.m. ET to discuss financial results.
• Present new clinical data on ZUNVEYL at the American Association of Geriatric Psychiatrists (AAGP) and the Neuroscience Education Institute (NEI) Spring Congress in Q2 2026.
• Expect two product approvals ex-US via partner CMS in Asia.
• Continue enrollment in the BEACON study (real-world effectiveness of ZUNVEYL).
• Plan to initiate the CONVERGE study (retrospective data analysis of ZUNVEYL in long-term care Alzheimer's patients).
• Plan to initiate the RESOLVE study (Phase 4 study to assess ZUNVEYL's effect on tolerability and behaviors in AD patients).
• Complete preclinical work with a sublingual ZUNVEYL formulation and advance it to the clinic in 2026.
• File the Annual Report on Form 10-K for the year ended December 31, 2025, on or about March 31, 2026.

Key Dates

Recommendation

Alpha Cognition demonstrates strong commercial momentum for ZUNVEYL, with significant revenue growth and expanding market penetration. The company is well-capitalized with a two-year cash runway, supporting its strategic initiatives and target of operational profitability by 2027. However, the substantial increase in operating and net losses due to commercialization investments, while expected, indicates that profitability is still some time away. The stock is a 'hold' as the positive commercial traction is balanced by ongoing losses and the inherent risks associated with biopharmaceutical development and market adoption, warranting continued monitoring of ZUNVEYL's performance and progress towards profitability.

Keywords

Alzheimers disease, ZUNVEYL, biopharmaceutical, neurodegenerative disorders, financial results, commercialization, PBM contract, clinical trials, ACOG, pharmaceutical